![](/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--e623d2450603cd9d4e6c86eae39da2c5b7f7bdd9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdERG9MY21WemFYcGxTU0lOTXpJd2VERTRNRjRHT2daRlZEb0pZM0p2Y0VraUVETXlNSGd4T0RBck1Dc3dCanNHVkRvTVozSmhkbWwwZVVraUMyTmxiblJsY2dZN0JsUTZESEYxWVd4cGRIbHBWVG9LYzNSeWFYQlVPZzVwYm5SbGNteGhZMlZKSWdsTWFXNWxCanNHVkRvTFpHVm1hVzVsU1NJZWFuQmxaenBtWVc1amVTMTFjSE5oYlhCc2FXNW5QVzltWmdZN0JsUT0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--daee5f4cd191d67586af9b48495fbde7d4763d64/lucas-vasques-453684-unsplash.jpg)
Search
Filter Results
Displaying 751–760 of 1000 results
-
-
-
-
-
-
Mar 12, 2019
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
ProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
-
-
-